CORE

🇺🇦   make metadata, not war

    1 research outputs found

    Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.

    Author
    Publication venue
    'American Society of Clinical Oncology (ASCO)'
    Publication date
    Field of study
    No full text
    Crossref
    corecore